Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3
Article Abstract:
A randomized, noninferiority trails is conducted to examine whether efficiency can be achieved with only 16 weeks of treatment with peginterferon alfa-2a and ribavirin on patients infected with hepatitis C virus (HCV) genotype 2 or 3. The results have shown an overall lower sustained virologic response rate than treatment with the standard 24-week regimen.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
Article Abstract:
Combination therapy with interferon alpha-2b and ribavirin may be more effective in patients with hepatitis C than interferon alpha-2b alone. Researchers randomly assigned 912 patients with chronic hepatitis C to either one of these treatments. The two drugs together were more effective than interferon alpha-2b alone, especially when taken for 48 weeks. Liver biopsies showed that patients taking both drugs had improved liver function. However, they were more likely to stop the treatment than those taking interferon alpha-2b alone.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1998
User Contributions:
Comment about this article or add new information about this topic: